Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody.

@article{Vzquez1998SyngeneicAM,
  title={Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody.},
  author={Ana Mar{\'i}a Carballido V{\'a}zquez and Alexis L{\'o}pez P{\'e}rez and Ana Moro Hernandez and Alfonso Guti{\'e}rrez Mac{\'i}as and M Cancho Alfonso and G. Bombino and Rafael Hinojosa P{\'e}rez},
  journal={Hybridoma},
  year={1998},
  volume={17 6},
  pages={
          527-34
        }
}
An IgM monoclonal antibody (MAb), named P3, has the characteristic to react specifically with a broad battery of N-glycolyl containing-gangliosides and with antigens expressed on breast tumors. When this MAb was administered alone in syngeneic mice, an specific IgG anti-idiotypic antibody (Ab2) response was induced, this Ab2 response was increased when P3 MAb was injected coupled to a carrier protein and in the presence of Freund's adjuvant. Spleen cells from these mice were used in somatic… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 40 CITATIONS

A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2014
VIEW 2 EXCERPTS
CITES BACKGROUND

Similar Papers

Loading similar papers…